Mark A. Kronenfeld, Director at Pacira Pharmaceuticals, Inc. (PCRX), bought 1,000 shares at $44.61 ($45K) on 2018-08-28, disclosed to the SEC on 2018-08-30.
Open-market purchase of $45k PCRX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| Filing → |
| PCRX | BUY | 2017-11-13 | $42K | — | Filing → |
| PCRX | SELL | 2016-06-08 | $42K | — | Filing → |
| PCRX | BUY | 2014-11-04 | $77K | — | Filing → |